License and Asset Acquisitions - Schedule of IPR&D Expense (Details) - USD ($) $ in Thousands |
12 Months Ended | ||
---|---|---|---|
Dec. 31, 2021 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total in process research and development | $ 75 | $ 23,380 | $ 3,600 |
Seralutinib | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total in process research and development | 0 | 5,000 | 0 |
GB004 | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total in process research and development | 0 | 15,000 | 0 |
GB1275 | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total in process research and development | 0 | 0 | 1,000 |
Other preclinical programs | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total in process research and development | $ 75 | $ 3,380 | $ 2,600 |